Navigation Links
Imprimis to Begin New Study of Its Topical Analgesic Drug
Date:9/19/2012

SOLANA BEACH, Calif., Sept. 19, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY:OTCQB) today announced the initiation of a clinical study of Impracor™, a topical cream that delivers a dose of the pain-relieving, anti-inflammatory drug ketoprofen. The study will measure the amount of ketoprofen found in the bloodstream following topical application of two different doses of the anti-inflammatory cream under different "real world' conditions, including normal activities, heat exposure to the application site and exercising on a treadmill. The amount of the drug in the bloodstream after taking an oral dose of ketoprofen will also be studied in healthy volunteers.

Impracor is designed to be applied to the site of muscle or joint pain, delivering a clinical dose of the active drug ketoprofen in its proprietary topical-delivery platform Accudel™ to the affected area. Current prescription ketoprofen (a non-steroidal anti-inflammatory drug, NSAID) is only available in an oral formulation in the US and is used to relieve pain and inflammation in various musculoskeletal conditions. Topical delivery of NSAIDs is recognized as safe pain medication that significantly reduces side effects, especially less stomach irritation, cardiac or liver problems compared with NSAIDs taken by mouth.

Imprimis believes its patented topical-delivery platform Accudel™ can also serve as a delivery vehicle for other medications.  Going forward, the company plans to employ a strategy of repurposing or reformatting existing FDA-approved generic drugs to be used in combination with Imprimis's delivery platform to create entirely new medications to address unmet therapeutic applications.

"We are pleased to achieve an important milestone for our company, which we expect to be the first of many such advances as we pursue FDA approval of our lead pain and anti-inflammatory product, Impracor™ and consider other potential product candidates utilizing our unique Accudel™ topical drug-delivery platform as we implement our business model," said Mark L. Baum, CEO of Imprimis.

Imprimis has selected Novum Pharmaceutical Research Services, based in Pittsburgh, PA, to conduct the study in 40 healthy human subjects, and PPD Laboratories to perform the analysis of the active drug in the blood samples. 

"We believe this study marks a major step forward to understanding the influence of different conditions on the absorption of topical ketoprofen," said Dr. Joachim Schupp, Imprimis's Chief Medical Officer. "Members of our Science and Regulatory Advisory Board did an outstanding job in assisting us with the trial protocol, culminating in the FDA clearing the protocol for initiation.  The Phase I clinics at Novum Pharmaceutical Research Services have a strong reputation for conducting pharmacokinetic and bioavailability studies," Dr. Schupp added.

"We expect the study will build on previous research that suggests the topical delivery of ketoprofen results in minimal levels of the drug in the bloodstream compared with what is known for an oral dose of the medication," said Dr.Schupp.

The study is expected to be completed during the fourth quarter of 2012.

"We are gratified to have been selected to work with Imprimis Pharmaceuticals to conduct this study for the evaluation of its lead pain product Impracor, and we are committed to the successful execution of this study, which is intended to provide data to meet FDA requirements," said Chris Hendy, Ph.D., President of Novum.

About Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals is a specialty pharmaceutical company developing non-invasive, topically delivered products. Our innovative patented Accudel cream formulation technology is designed to enable highly targeted site-specific treatment. Impracor, our lead pain product candidate, utilizes the Accudel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. We intend to leverage the Accudel platform technology to expand and create a portfolio of topical products for a variety of indications. 

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products and to enter into strategic alliances and transactions, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis's reports filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no  obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact: Mark L. Baum
Imprimis Pharmaceuticals, Inc.
(858) 433-2800

 


'/>"/>
SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Imprimis Names Two Experts To Its Science And Regulatory Board
2. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
3. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
4. Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
5. Life Technologies Begins Shipping Ion Proton System
6. Phase 3 Clinical Trial Begins in Early Form of Dementia
7. Medical Alarm Concepts Begins Shipments To Europe - Company Ordering Additional Inventory To Keep Up With Growing Demand
8. VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
9. Countdown Begins For AdvaMed 2012: The Medtech Conference
10. K-V Pharmaceutical Class A and Class B Common Stock Begin Trading on the OTC Markets
11. Siteman Cancer Center at Barnes-Jewish and Washington University Begins Imaging with First ViewRay System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 ... "US Market Overview for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices ... ... The full report suite on the ... fluid external drainage systems, intracranial pressure monitoring devices, detachable coils, ...
(Date:11/30/2016)... Nov. 30, 2016 Varian Medical Systems (NYSE: ... America,s Most JUST Company in the Healthcare Equipment and ... magazine,s inaugural "JUST 100 List." The rankings are ... surveys ever conducted on attitudes towards corporate behavior, involving ... list ranks U.S companies against their peers within 32 ...
Breaking Medicine Technology:
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 ... ... over 5,100 hot meals to needy individuals and families from eight different sites ... Florida on Thanksgiving Day. Over 1,000 volunteers worked very hard on Thanksgiving morning ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ‘Tis the ... winners of $1,000 each from the National Family Partnership and the Drug Enforcement Administration ... who decorated their homes and the 10 winning schools who decorated their campuses with ...
(Date:11/30/2016)... ... ... "I hate when the mixture of saliva and toothpaste runs down my toothbrush ... N.J. "I thought that there had to be a way to prevent this mess, ... to prevent saliva and toothpaste from running down the brush handle onto the hand ...
(Date:11/30/2016)... CA (PRWEB) , ... November 30, 2016 , ... ... disorder and mental health treatment has announced the opening of a new residential ... treatment for girls with mental health issues such as severe anxiety, depression, bi-polar ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... community that the FDA Binding Guidance goes into effect next month. Sponsors whose ... in the FDA Data Standards Catalog. The current FDA Data Standards Catalog specifies ...
Breaking Medicine News(10 mins):